Search Results for: Neuralstem

Interview with Neuralstem CEO Richard Garr

I invited Neuralstem CEO, Richard Garr, to do a Q&A interview and he kindly accepted. The interview provides some novel insights into this major biotech in the stem cell sector. 1. How is Neuralstem doing today? What programs are underway that you find particularly exciting?  Garr: Neuralstem is moving on all cylinders these days on …

Interview with Neuralstem CEO Richard Garr Read More »

Interview with Ted Harada Part 2: Right To Try, Neuralstem, and How He’s Doing

Harada-Family-e1479769086296

This is Part 2 of my interview with ALS and stem cell advocate, Ted Harada. You can read Part 1 of my talk with Ted on where things stand today with ALS, the FDA, and the Ice Bucket Challenge. What’s your opinion of the “Right To Try” law in Colorado and the concept more generally? …

Interview with Ted Harada Part 2: Right To Try, Neuralstem, and How He’s Doing Read More »

Neuralstem flirting with noncompliance via Right To Try Law?

Is Neuralstem flirting with noncompliance via a Right To Try Law in Colorado? Colorado is an independent-minded state. For example, it is one of only a few states including Washington State with legalized marijuana use. More recently, Colorado passed a new law supported by the ultra-conservative Goldwater Institute, the so-called Right To Try Law. This law …

Neuralstem flirting with noncompliance via Right To Try Law? Read More »

Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer

What’s going on these days with biotech companies working on stem cell-based products? Geron’s and Advanced Cell Technology (ACT)’s FDA-approved trials presumably continue. As expected, no news yet. It’s too soon. Two important questions regarding both these companies are (1) did they apply for CIRM funding and (2) if so, how did the review process …

Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer Read More »

Does NurOwn from BrainStorm Cell Therapeutics still provide hope for ALS?

Chaim Lebovits, CEO of BrainStorm Cell Therapeutics.

What is the cell therapy for ALS called NurOwn? How strong is its potential as a treatment for ALS? I’ve been following the biotech BrainStorm Cell Therapeutics for many years. Patients keep asking me about NurOwn ALS prospects. They’re looking for hope. Today’s post is a close look at NurOwn and at BrainStorm as a …

Does NurOwn from BrainStorm Cell Therapeutics still provide hope for ALS? Read More »

Weekly reads: death in CRISPR trial, sickle cell, nose picking & dementia, epilepsy

CRISPR gene editing

As both a scientist who works on stem cells, cancer, and CRISPR, and a research advocate I’ve been fortunate to meet many patient advocates over the years. Some have been participants in clinical trials themselves. Benefits & risks of clinical trial participation It is very sobering to find out that a clinical trial participant has …

Weekly reads: death in CRISPR trial, sickle cell, nose picking & dementia, epilepsy Read More »

Overplaying N=1 in the stem cell therapy world

stem cell therapy

The regular emails and phone calls I get from patients asking questions about stem cell therapy are a powerful reminder of the fact that research in our field can be very personal. Sometimes individuals who receive experimental stem cell therapy (or other cell therapies) and seem to have a positive outcome can end up becoming …

Overplaying N=1 in the stem cell therapy world Read More »

24 cell therapy & stem cell stocks I’m following

stem cell stocks

Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. Stem cell biotechs These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell …

24 cell therapy & stem cell stocks I’m following Read More »

MD Stem Cells purported Right To Try program

Steven-Levy-Jeffrey-Weiss, SCOTS trial

I’ve been concerned about a stem cell group called MD Stem Cells for many years. Now it comes under more scrutiny from a new must-read piece by Donna Young over at S&P Global. Young’s article reports a puzzling, purported right-to-try (RTT) program that MD Stem Cells appears to working on with Richard Garr. Note that …

MD Stem Cells purported Right To Try program Read More »